24/7 Market News Snapshot 08 August, 2025 – Nutriband Inc. Common Stock (NASDAQ:NTRB)

August 8, 2025

DENVER, Colo., 08 August, 2025 (www.247marketnews.com) – (NASDAQ:NTRB) are discussed in this article.
Nutriband Inc. is experiencing significant momentum in its stock market performance, trading at $7.955, reflecting an impressive 11.57% increase from the previous session’s close of $7.130. This surge is indicative of robust investor interest, supported by a current trading volume of 1.36 million shares, suggesting strong market activity and the potential for continued gains. Analysts note that key technical support levels may lie around $7.00, with resistance potentially approaching $8.00. Traders are advised to monitor both price movements and fluctuations in volume as indicators of the stock’s bullish trend, which may suggest further upside potential in the near future.

In parallel, Nutriband has made strides in its product development by announcing a critical milestone for its lead offering, AVERSA™ FENTANYL. The U.S. Food and Drug Administration (FDA) has granted a Type C Meeting, scheduled for September 18, 2025, aimed at discussing feedback regarding the Chemistry, Manufacturing, and Controls (CMC) plans for this innovative abuse-deterrent fentanyl transdermal system.

The AVERSA™ FENTANYL product, developed in partnership with Kindeva, integrates Nutriband’s proprietary AVERSA™ technology to address opioid abuse, diversion, and accidental exposure risks through the addition of aversive agents in transdermal formulations. Positioned to be the first abuse-deterrent opioid patch commercially available, AVERSA FENTANYL is anticipated to generate peak annual sales between $80 million and $200 million, starting with the U.S. market before scaling to meet global needs.

Safeguarding its innovation, Nutriband holds an extensive international patent portfolio covering 46 countries, including key markets across North America, Europe, and Asia. This robust intellectual property framework underlines Nutriband’s commitment to advancing patient safety and effective pain management solutions. As preparations for the FDA meeting continue, the company remains focused on delivering safer alternatives in the pharmaceutical landscape, ensuring access to critical pain management therapies while mitigating the risks associated with opioid misuse.

Related news for (NTRB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.